KR102694692B1 - 리포좀 내에 캡슐화된 트리테르페노이드 항진균제의 주사가능한 조성물 - Google Patents

리포좀 내에 캡슐화된 트리테르페노이드 항진균제의 주사가능한 조성물 Download PDF

Info

Publication number
KR102694692B1
KR102694692B1 KR1020207022062A KR20207022062A KR102694692B1 KR 102694692 B1 KR102694692 B1 KR 102694692B1 KR 1020207022062 A KR1020207022062 A KR 1020207022062A KR 20207022062 A KR20207022062 A KR 20207022062A KR 102694692 B1 KR102694692 B1 KR 102694692B1
Authority
KR
South Korea
Prior art keywords
injectable composition
compound
formula
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207022062A
Other languages
English (en)
Korean (ko)
Other versions
KR20200105875A (ko
Inventor
라제시와르 마더램
Original Assignee
싸이넥시스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 싸이넥시스, 인크. filed Critical 싸이넥시스, 인크.
Publication of KR20200105875A publication Critical patent/KR20200105875A/ko
Application granted granted Critical
Publication of KR102694692B1 publication Critical patent/KR102694692B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
KR1020207022062A 2018-01-02 2018-12-21 리포좀 내에 캡슐화된 트리테르페노이드 항진균제의 주사가능한 조성물 Active KR102694692B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862612893P 2018-01-02 2018-01-02
US62/612,893 2018-01-02
PCT/US2018/067216 WO2019135954A1 (en) 2018-01-02 2018-12-21 Injectable compositions of triterpenoid antifungals encapsulated in liposomes

Publications (2)

Publication Number Publication Date
KR20200105875A KR20200105875A (ko) 2020-09-09
KR102694692B1 true KR102694692B1 (ko) 2024-08-14

Family

ID=65024141

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207022062A Active KR102694692B1 (ko) 2018-01-02 2018-12-21 리포좀 내에 캡슐화된 트리테르페노이드 항진균제의 주사가능한 조성물

Country Status (27)

Country Link
US (3) US20200338002A1 (https=)
EP (2) EP4137123A1 (https=)
JP (3) JP7378401B2 (https=)
KR (1) KR102694692B1 (https=)
CN (2) CN115998684A (https=)
AU (1) AU2018399599B2 (https=)
CA (1) CA3087176A1 (https=)
DK (1) DK3735226T3 (https=)
EA (1) EA202091626A1 (https=)
ES (1) ES2927051T3 (https=)
HR (1) HRP20221295T1 (https=)
HU (1) HUE060400T2 (https=)
IL (2) IL275758B2 (https=)
LT (1) LT3735226T (https=)
MA (1) MA51514A (https=)
MD (1) MD3735226T2 (https=)
MX (1) MX2020006992A (https=)
PL (1) PL3735226T3 (https=)
PT (1) PT3735226T (https=)
RS (1) RS63687B1 (https=)
SA (1) SA520412362B1 (https=)
SG (1) SG11202006313WA (https=)
SI (1) SI3735226T1 (https=)
SM (1) SMT202200427T1 (https=)
TW (2) TWI857944B (https=)
UA (1) UA126096C2 (https=)
WO (1) WO2019135954A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3087176A1 (en) * 2018-01-02 2019-07-11 Scynexis, Inc. Injectable compositions of triterpenoid antifungals encapsulated in liposomes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090060998A1 (en) 2004-01-14 2009-03-05 Gilead Sciences, Inc. Lipid-based dispersions useful for drug delivery
WO2010019204A1 (en) 2008-08-12 2010-02-18 Merck Sharp & Dohme Corp. Antifungal agents
US20160207956A1 (en) 2015-01-19 2016-07-21 Scynexis, Inc. Novel salts and polymorphs of scy-078

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756472A (en) 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
US7718189B2 (en) * 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
JP5245057B2 (ja) 2006-04-03 2013-07-24 メルク・シャープ・アンド・ドーム・コーポレーション 抗真菌剤
CN101861150B (zh) * 2007-09-28 2014-07-16 默克夏普和道赫莫公司 抗真菌制剂
JP2011518844A (ja) * 2008-04-25 2011-06-30 ナノバイオ コーポレーション 真菌、酵母および糸状菌感染症を治療するためのナノエマルション
AU2009275230A1 (en) * 2008-07-23 2010-01-28 Targeted Delivery Technologies Limited Methods of administering topical antifungal formulations for the treatment of fungal infections
ES2593027T3 (es) * 2009-03-30 2016-12-05 Eisai R&D Management Co., Ltd. Composición liposomal
CA3087176A1 (en) * 2018-01-02 2019-07-11 Scynexis, Inc. Injectable compositions of triterpenoid antifungals encapsulated in liposomes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090060998A1 (en) 2004-01-14 2009-03-05 Gilead Sciences, Inc. Lipid-based dispersions useful for drug delivery
WO2010019204A1 (en) 2008-08-12 2010-02-18 Merck Sharp & Dohme Corp. Antifungal agents
US20160207956A1 (en) 2015-01-19 2016-07-21 Scynexis, Inc. Novel salts and polymorphs of scy-078

Also Published As

Publication number Publication date
US20230277455A1 (en) 2023-09-07
LT3735226T (lt) 2022-11-10
EP3735226B1 (en) 2022-08-10
KR20200105875A (ko) 2020-09-09
JP7378401B2 (ja) 2023-11-13
SMT202200427T1 (it) 2022-11-18
JP2024012452A (ja) 2024-01-30
DK3735226T3 (da) 2022-10-24
JP2025106349A (ja) 2025-07-15
HUE060400T2 (hu) 2023-02-28
SA520412362B1 (ar) 2022-12-15
US20250082574A1 (en) 2025-03-13
CN115998684A (zh) 2023-04-25
HRP20221295T1 (hr) 2022-12-23
SI3735226T1 (sl) 2022-11-30
RS63687B1 (sr) 2022-11-30
BR112020013448A2 (pt) 2020-12-01
EA202091626A1 (ru) 2020-09-22
IL275758B2 (en) 2025-07-01
IL318793A (en) 2025-04-01
WO2019135954A1 (en) 2019-07-11
MD3735226T2 (ro) 2023-03-31
PT3735226T (pt) 2022-09-20
TW201929853A (zh) 2019-08-01
TW202434242A (zh) 2024-09-01
EP4137123A1 (en) 2023-02-22
MX2020006992A (es) 2020-09-09
UA126096C2 (uk) 2022-08-10
CA3087176A1 (en) 2019-07-11
NZ765771A (en) 2024-09-27
JP2021508728A (ja) 2021-03-11
MA51514A (fr) 2021-04-07
IL275758A (en) 2020-08-31
IL275758B1 (en) 2025-03-01
AU2018399599A1 (en) 2020-07-16
ES2927051T3 (es) 2022-11-02
TWI857944B (zh) 2024-10-11
SG11202006313WA (en) 2020-07-29
CN111655237B (zh) 2023-02-03
EP3735226A1 (en) 2020-11-11
PL3735226T3 (pl) 2022-12-19
CN111655237A (zh) 2020-09-11
TWI862280B (zh) 2024-11-11
US20200338002A1 (en) 2020-10-29
AU2018399599B2 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
US20260000656A1 (en) Antifungal agents with enhanced activity in acidic ph
JP2025106349A (ja) リポソームの中にカプセル化されたトリテルペノイド抗真菌薬の注射可能な組成物
KR20190133251A (ko) 조합하여 사용되는 항진균제
HK40090116A (en) Injectable compositions of triterpenoid antifungals encapsulated in liposomes
HK40040387A (en) Injectable compositions of triterpenoid antifungals encapsulated in liposomes
HK40040387B (en) Injectable compositions of triterpenoid antifungals encapsulated in liposomes
HK40036677B (en) Injectable compositions of triterpenoid antifungals encapsulated in liposomes
EA045936B1 (ru) Инъецируемые композиции, обладающие противогрибковой активностью, и способы их получения и применения
HK40036677A (en) Injectable compositions of triterpenoid antifungals encapsulated in liposomes
BR112020013448B1 (pt) Composição injetável, método para preparar uma composição injetável, e, uso da composição injetável
Grillot et al. Systemic antifungal agents
HK40030410A (en) Antifungal agents with enhanced activity in acidic ph
HK40030410B (en) Antifungal agents with enhanced activity in acidic ph
EA047126B1 (ru) Противогрибковое средство для лечения или профилактики инфекции вульвовагинального кандидоза

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601